Well Referenced

Tag: regenerative therapy

Shockwave Therapy Combined with Autologous Adipose-Derived Mesenchymal Stem Cells Is Better than with Human Umbilical Cord Wharton’s Jelly-Derived Mesenchymal Stem Cells on Knee Osteoarthritis

This 2020 preclinical study evaluated the efficacy of combining extracorporeal shockwave therapy (ESWT) with either autologous adipose-derived mesenchymal stem cells (ADMSCs) or human umbilical cord Wharton’s jelly-derived mesenchymal stem cells (WJMSCs) in treating early-stage knee osteoarthritis (KOA) in a rat model. The ESWT+ADMSCs group demonstrated superior outcomes, including increased trabecular

Read More »
June 26, 2025 No Comments

Human Umbilical Cord-Derived Mesenchymal Stem Cells in the Treatment of Multiple Sclerosis Patients: Phase I/II Dose-Finding Clinical Study

This 2024 Phase I/II clinical trial assessed the safety and efficacy of human umbilical cord-derived mesenchymal stem cells (UC-MSCs) in patients with multiple sclerosis (MS). Participants were divided into two groups: Group A received two intrathecal doses of UC-MSCs, while Group B received a single dose. Both groups also received

Read More »
June 26, 2025 No Comments

Stem Cell Ophthalmology Treatment Study (SCOTS): Bone Marrow-Derived Stem Cells in the Treatment of Age-Related Macular Degeneration

This 2020 study evaluated the safety and efficacy of autologous bone marrow-derived stem cells (BMSCs) in 32 eyes from patients aged 69–90 with dry age-related macular degeneration (AMD). BMSCs were administered via retrobulbar, subtenons, intravitreal, subretinal, and intravenous routes. After treatment, 63% of eyes showed improvement in visual acuity, 34%

Read More »
June 26, 2025 No Comments

Stem Cell Ophthalmology Treatment Study (SCOTS): Bone Marrow-Derived Stem Cells in the Treatment of Stargardt Disease

The SCOTS and SCOTS2 trials evaluated the safety and efficacy of autologous bone marrow-derived stem cells (BMSCs) in 34 eyes from patients with Stargardt Disease. BMSCs were administered via retrobulbar, subtenons, intravitreal, subretinal, and intravenous routes. After one year, 61.8% of eyes showed visual improvement, 23.5% remained stable, and 14.7%

Read More »
June 26, 2025 No Comments

Treatment of Diabetic Impotence with Umbilical Cord Blood Stem Cell Intracavernosal Transplant: Preliminary Report of 7 Cases

This 2010 pilot study assessed the safety and efficacy of intracavernosal injections of human umbilical cord blood stem cells (hUCBSCs) in seven male patients (ages 57–87) with type 2 diabetes mellitus and refractory erectile dysfunction (ED). Each patient received a single injection of 1.5×10⁷ hUCBSCs without immunosuppression. Over a 9-month

Read More »
June 26, 2025 No Comments

Effects of Stem Cell Treatment in Human Patients With Peyronie Disease

This prospective pilot study evaluated the safety and efficacy of intracavernosal injections of placental matrix-derived mesenchymal stem cells (PM-MSCs) in five male patients aged 45–59 with Peyronie’s disease (PD). Patients received a single PM-MSC injection and were followed at 6 weeks, 3 months, and 6 months. Significant improvements were observed

Read More »
June 26, 2025 No Comments

The Effect of Intracavernosal Injection of Stem Cell in the Treatment of Erectile Dysfunction in Diabetic Patients: A Randomized Single-blinded Clinical Trial

This 2021 randomized, single-blind clinical trial evaluated the safety and efficacy of intracavernosal injection of autologous oral mucosa-derived mesenchymal stem cells (MSCs) in 20 diabetic men with erectile dysfunction (ED) unresponsive to standard treatments. Participants were divided into intervention (n=10) and control (n=10) groups. The intervention group received a single

Read More »
June 26, 2025 No Comments

Safety and Efficacy of 2 Intracavernous Injections of Allogeneic Wharton’s Jelly-Derived Mesenchymal Stem Cells in Diabetic Patients with Erectile Dysfunction: Phase 1/2 Clinical Trial

This 2021 phase 1/2 clinical trial evaluated the safety and efficacy of two intracavernous injections of allogeneic Wharton’s jelly-derived mesenchymal stem cells (WJ-MSCs) in 22 diabetic men with refractory erectile dysfunction (ED). The procedure was well-tolerated, with only minimal and transient adverse events such as redness and bruising at the

Read More »
June 26, 2025 No Comments

Oxygen-Ozone Therapy in the Rehabilitation Field: State of the Art on Mechanisms of Action, Safety and Effectiveness in Patients with Musculoskeletal Disorders

This systematic review published in Biomolecules (2021) analyzes the safety, mechanisms of action, and efficacy of oxygen-ozone (O₂O₃) therapy in patients with musculoskeletal disorders, particularly low back pain and knee osteoarthritis. The therapy works by inducing moderate oxidative stress, which produces signaling molecules that modulate inflammation and oxidative stress pathways,

Read More »
June 26, 2025 No Comments

Ozonized autohemotransfusion improves hemorheological parameters and oxygen delivery to tissues in patients with peripheral occlusive arterial disease

This 2001 randomized controlled trial titled “Ozonized autohemotransfusion improves hemorheological parameters and oxygen delivery to tissues in patients with peripheral occlusive arterial disease” (Annals of Hematology, DOI: [10.1007/s002770100377*) evaluated the impact of ozonized autohemotransfusion in 27 patients with peripheral occlusive arterial disease (POAD) compared to 20 healthy controls. Patients receiving

Read More »
June 26, 2025 No Comments